Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. is a U.S.-based clinical-stage biotechnology company focused on developing RNAi-based immuno-oncology therapies. Through its subsidiary MirImmune, LLC, the company advances INTASYL drug candidates such as PH-762 and PH-894 for potential use in cancer treatment.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaINTASYL-based RNA interference technology used to silence target genes in immune and cancer cells.
Lead and pipeline drug candidates being developed for immuno-oncology applications.
IND-enabling studies, translational research, and early-stage development work.
Patents and pending applications covering compounds, technologies, and geographic protection.
Asiakkaat
Phio does not sell commercial products today; its primary counterparties are clinical collaborators, research vendors, regulators, and capital providers that support drug development. If its candidates advance, the eventual customers would be oncology patients through physicians and healthcare systems, with adoption depending on clinical efficacy, safety, and regulatory approval.
Research organizations and collaborators that support preclinical studies, assay work, and trial execution.
U.S. and other regulators that review IND submissions and clinical packages for PH-762 and PH-894.
Oncologists and cancer centers that would use approved therapies if the pipeline reaches commercialization.
Equity and debt investors that fund ongoing R&D and public-company operations.
Strategia
Phio’s strategy centers on advancing its lead immuno-oncology candidate PH-762 while continuing preclinical work on PH-894 and protecting the INTASYL platform through patents. The company also prioritizes capital preservation and financing access so it can fund development through regulatory milestones and potential partnering opportunities.
The lead candidate is the main path to value creation and potential partnering.
Broadens the pipeline and creates a second development asset.
Patent coverage supports exclusivity and future licensing leverage.
Clinical biotechnology requires ongoing external capital before product revenue exists.
Maantiede
Phio is headquartered in the United States and concentrates its development and patent activity there, while also maintaining patent coverage in Canada, Europe, Japan, and other markets. Its operational footprint is primarily U.S.-based, but its intellectual property strategy reflects a broader international protection approach for future partnering and commercialization.
Riskit
Phio faces the typical risks of a pre-commercial biotech company: clinical and regulatory uncertainty, dependence on external financing, and the possibility that candidates do not demonstrate sufficient safety or efficacy. The company also has specific listing and liquidity risks tied to Nasdaq compliance, which can affect market access and financing flexibility.
- Clinical development failureVaikutus: Kriittinen
Drug candidates may not show sufficient efficacy or safety in preclinical or clinical testing.
Kohdistuu - Financing dependenceVaikutus: KorkeaTodennäköisyys: Korkea
Operations are funded primarily through external capital until any product revenue exists.
Kohdistuu - Nasdaq continued listing complianceVaikutus: KorkeaTodennäköisyys: Kohtalainen
The company must maintain minimum bid price and equity requirements to remain listed.
Kohdistuu: Nasdaq Capital Market listing
- Supply and trade policy disruptionVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Research and development inputs may be delayed or become more expensive.
Kohdistuu: Preclinical and clinical development operations
Kirjanpito
Harkinnanvaraiset erätCRO and study costs are estimated based on work performed and can shift period expense.
Vaikutus: Affects operating expense timing and liabilities
Public biotech companies often use equity awards to conserve cash.
Vaikutus: Affects operating expenses and equity
Limited cash and recurring losses require management judgment about funding sufficiency.
Vaikutus: Affects disclosure and investor perception
Capital raises and share consolidations change share count and per-share metrics.
Vaikutus: Affects dilution and comparability
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Xilio Therapeutics, Inc.
XLO · Pharmaceutical Preparations
Xilio Therapeutics is a U.S.-based biotechnology company focused on developing tumor-activated immunotherapies for cancer.
IO Biotech, Inc.
IOBTQ · Pharmaceutical Preparations
Inovio Pharmaceuticals, Inc
INO · Pharmaceutical Preparations
INOVIO Pharmaceuticals is a clinical-stage biotechnology company developing DNA medicines designed to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases.
Oncotelic Therapeutics, Inc.
OTLC · Pharmaceutical Preparations
Inmune Bio, Inc.
INMB · Biological Products, (No Diagnostic Substances)
Intensity Therapeutics, Inc
INTS · Biological Products, (No Diagnostic Substances)
Päivitetty: 24.9.2026